
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. showcases a strong financial outlook through its innovative PREDATOR platform, which enables the design of conditionally activated molecules that target the tumor microenvironment, addressing limitations in traditional therapies. The company has reported positive developments in operational metrics, particularly with the ability to achieve significant progression in the design and application of its INDUKINE molecules, indicating ongoing advancement in its therapeutic pipeline. Furthermore, the company’s focus on stimulating both adaptive and innate immunity enhances its potential to capture market demand, positioning Werewolf Therapeutics favorably within the competitive biopharmaceutical landscape.
Bears say
The financial outlook for Werewolf Therapeutics appears negative due to multiple indicators of declining performance. The company has lowered its full-year same-store revenue growth guidance from a range of (0.35%)-1.15% to a new range of (0.20%)-0.40%, highlighting a deteriorating revenue forecast. Additionally, revenue has decreased by 30 basis points year-over-year while expenses have risen by 3.8%, resulting in a notable decline in net operating income by 2.6%.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares